Biomea Fusion, Inc. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer
Biomea Fusion, Inc. (BMEA) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer of $0 as of 2021-09-30, per its 10-Q filed 2021-11-03.
Discontinued › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger · last filed 2021-11-03
- 2021-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $0.00.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer |
|---|---|
| 2021-09-30 | $0.00 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |